Minerva cardiology and angiology最新文献

{"title":"Trends in vascular dementia-related mortality in the United States from 2005 to 2020.","authors":"Ali Salman, Dua Batool Zaide, Rayaan Imran, Hoor Ul Ain, Muhammad O Bhatti, Laiba Batool, Beena Muntaha Nasir, Laiqa Tariq, Shaaf Ahmad, Mohammad S Khan Khakwani, Muhammad Qasim, Syed A Hassan, Namra S Raja, Minahil Aamir, Muhammad W Nasir, Shayan Marsia","doi":"10.23736/S2724-5683.25.06719-5","DOIUrl":"https://doi.org/10.23736/S2724-5683.25.06719-5","url":null,"abstract":"<p><strong>Background: </strong>The aging population in the USA has led to a concomitant rise in the prevalence of vascular dementia (VaD), yet there remains a paucity of investigation into mortality trends associated with VaD among adults.</p><p><strong>Methods: </strong>This cross-sectional analysis utilized death certificate data from the Centers for Disease Control and Prevention's WONDER database. VaD-associated mortality was identified using the International Statistical Classification of Diseases and Related Health Problems-10th revision (ICD-10) code F01. Crude, and age-adjusted VaD-associated mortality rates per 100,000 and their corresponding 95% confidence intervals (CI) were computed. Age-adjusted mortality rates (AAMRs) were standardized to the 2000 US census population.</p><p><strong>Results: </strong>From 2005 to 2020, there were 375,575 deaths attributed to VaD among older adults. We observed a gradual increase in AAMR (APC: 3.70, 95% CI [-4.14, 5.21]) from 2005 to 2015, succeeded by a pronounced escalation (APC: 9.07, 95% CI [6.09, 17.62]) until 2020. The highest AAMR was noted in the West (17.65, 95% CI [17.55, 17.76]), followed by the Midwest (AAMR: 12.66, 95% CI [12.58, 12.75]), the South (AAMR: 12.60, 95% CI [12.54, 12.67]), and the Northeast (AAMR: 8.60, 95% CI [8.53, 8.68]). Metropolitan areas exhibited higher AAMRs (10.9, 95% CI [10.8, 11.0]) compared to non-metropolitan areas (8.1, 95% CI [8.00, 8.3]). Among age groups, individuals aged 75-85 and older showed the highest overall AAMR (99.80, 95% CI [99.47, 100.14]). In addition, non-Hispanic Black or African-American subset of the population showed the highest overall AAMR (8.12, [95% CI: 8.03, 8.20]).</p><p><strong>Conclusions: </strong>Our findings underscore the imperative for targeted public health interventions aimed at addressing regional disparities and age-specific vulnerabilities to mitigate the mounting burden of VaD-related mortality.</p>","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144151066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Right heart failure: lights and shadows.","authors":"Francesca Giordana, Sebastian Cinconze, Lucia Coppini, Chiara Bernelli","doi":"10.23736/S2724-5683.25.06644-X","DOIUrl":"https://doi.org/10.23736/S2724-5683.25.06644-X","url":null,"abstract":"<p><p>Right heart function is essential for overall heart health and plays a crucial role in the prognosis of patients with heart failure. A comprehensive assessment of the right ventricle (RV) that includes various clinical and hemodynamic parameters, as well as imaging techniques, provides important insights into the structure and function of the right heart. Advanced imaging methods, such as cardiac MRI, offer further clarity regarding the morphology and performance of the right heart. Interventional therapies have transformed treatment options and the prognosis for patients with advanced RV failure, and these therapies should be integrated into a comprehensive care plan. Ongoing research into the molecular and genetic factors contributing to right heart dysfunction is expected to reveal new therapeutic targets. Continued advancements in imaging and treatment options are vital for enhancing patient outcomes. In this review, we provide a detailed analysis of RV function, diagnosis, and therapy for RV failure.</p>","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing cardiovascular screening in master athletes: the role of exercise stress echocardiography.","authors":"Valentina Pescatore, Mattia Grassi, Stefano Palermi, Marco Vecchiato, Erica Brugin, Silvia Compagno, Carlo Zanella, Salvatore Saccà, Antonello D'Andrea, Giulia Quinto, Andrea Ermolao, Franco Giada","doi":"10.23736/S2724-5683.25.06747-X","DOIUrl":"https://doi.org/10.23736/S2724-5683.25.06747-X","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular (CV) disease is a significant risk even among seemingly healthier populations like master athletes, who face unique CV challenges due to their advanced age and high-intensity physical activities. Exercise stress echocardiography (ESE) has emerged as a valuable diagnostic tool to detect exercise-induced coronary artery disease (CAD), offering advantages over traditional exercise stress testing (EST) by integrating echocardiographic imaging. This article aimed to assess the diagnostic value and efficacy of ESE for detecting CAD in master athletes who exhibit exercise-induced alterations during pre-participation screening (PPS) EST.</p><p><strong>Methods: </strong>This retrospective study analyzed 521 master athletes (aged 35 years and older) who underwent annual CV assessments including EST as part of their PPS at Noale Hospital, Venice, Italy, from September 2020 to August 2023. Participants who showed exercise-induced alterations suspicious for CAD on EST were further evaluated using ESE.</p><p><strong>Results: </strong>Of the 521 athletes screened, 58 (11.1%) exhibited suspicious alterations for CAD during EST. ESE further identified 13 athletes with wall motion abnormalities (WMA), of whom 10 were subsequently diagnosed with critical CAD and received appropriate interventions. The positive predictive value of ESE was 0.77. Comparatively, athletes with WMA had significantly higher CV risk scores. No major adverse CV events (MACE) were reported during the 43.9-month follow-up.</p><p><strong>Conclusions: </strong>ESE is an effective third-line diagnostic tool in master athletes, demonstrating a high diagnostic yield for identifying significant CAD. Its integration into routine CV screening for master athletes can enhance the detection of underlying pathologies, potentially leading to timely and life-saving interventions.</p>","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum uric acid and prognosis in coronary bifurcation lesions treated with drug-eluting stents.","authors":"Attilio Lauretti, Iginio Colaiori, Francesco Versaci","doi":"10.23736/S2724-5683.25.06866-8","DOIUrl":"https://doi.org/10.23736/S2724-5683.25.06866-8","url":null,"abstract":"","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144017421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypercholesterolemia and cardiovascular disease: the dilemma of effective treatment for target achievement according to guidelines and national healthcare policies and a call to action.","authors":"Laura A Dalla Vecchia, Francesco DE Stefano, Maurizio Bussotti, Cosmo Godino, Marco Bernardi, Luigi Spadafora, Edvige Palazzo Adriano, Pasquale Guarini, Roberto F Pedretti","doi":"10.23736/S2724-5683.25.06704-3","DOIUrl":"https://doi.org/10.23736/S2724-5683.25.06704-3","url":null,"abstract":"<p><p>The burden of cardiovascular disease (CVD) remains a worldwide challenge. CVDs, in particular atherosclerotic CVD, are still an important cause of mortality and morbidity. The increase in life expectancy is a further determining factor in the epidemiology of CVDs in some countries, such as Italy, which increases the urgency of intervening on modifiable risk factors. Among these, hypercholesterolemia is present in a significant percentage of CVD patients. A linear relationship between the risk of acute events and the plasma level of low-density lipoproteins cholesterol (LDL-C) is well known. The reduction of LDL-C levels leads to a decrease in mortality and morbidity. The overall recommendation is to treat hypercholesterolemia intensively and as early as possible. Statins, ezetimibe, bempedoic acid, pro-protein convertase subtilisin/kexin 9 inhibitors (i.e., the monoclonal antibodies alirocumab and evolocumab, or the small interfering RNA inclisiran) are all available for reaching LDL-C targets according to risk profile. While the real-world data confirm the safety of currently recommended LDL-C targets, data on their actual achievement are discouraging, less than half of patients on therapy reach the LDL-C targets recommended by the most recent ESC/EAS Guidelines. The causes of this critical discrepancy are multiple, arising from the various components that characterize the complex relationship between patient and physician within the healthcare system. A call to action is needed. Doctors should be continuously updated on the latest evidence, follow recommendations and engage the patient in the therapeutic process. Regular monitoring of the effects of the prescribed therapy, also through e-health and telemedicine tools, is essential, as well as changing therapy when LDL-C is not adequately controlled. Finally, health systems should align with guidelines and promote good clinical practices, overcoming a silo system, to impact outcomes in terms of overall sustainability.</p>","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143978787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decoding immune involvement in acute coronary syndromes: insights from novel biomarker discovery.","authors":"Marco Borgi, Francesco Mannaioli, Francesco Versaci","doi":"10.23736/S2724-5683.25.06726-2","DOIUrl":"https://doi.org/10.23736/S2724-5683.25.06726-2","url":null,"abstract":"","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of percutaneous coronary intervention in spontaneous coronary artery dissection: between Scylla and Charybdis.","authors":"Marco Lombardi, Jorge Chavez-Solsol, Pablo Salinas, Enrico Cerrato, Rocco Vergallo, Italo Porto, Ferdinando Varbella, Nieves Gonzalo, Javier Escaned, Fernando Macaya-Ten","doi":"10.23736/S2724-5683.24.06680-8","DOIUrl":"https://doi.org/10.23736/S2724-5683.24.06680-8","url":null,"abstract":"<p><p>Spontaneous coronary artery dissection (SCAD) is a distinct and increasingly recognized cause of acute coronary syndromes, primarily affecting young and middle-aged women with few cardiovascular risk factors. While SCAD often resolves spontaneously with conservative management, percutaneous coronary intervention (PCI) is sometimes necessary, especially in patients with ongoing ischemia or high-risk anatomical features. This review summarizes the current state of knowledge regarding the interventional approach in SCAD, emphasizing the rationale for conservative treatment, and the indications for and challenges associated with PCI. It also provides practical recommendations, particularly highlighting technical aspects of PCI in SCAD, the critical role of intracoronary imaging, and the modality and timing of post-PCI surveillance.</p>","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of biochemical and economic outcomes in patients treated with PCSK9 inhibitors in a real clinical practice setting.","authors":"Melania Dovizio, Marta Nugnes, Biagio Iacolare, Carmela Nappi, Stefania Saragoni, Margherita Andretta, Antonietta Barbieri, Fausto Bartolini, Gianmarco Chinellato, Mariarosaria Cillo, Stefania Dell'orco, Stefano Grego, Antonella Lavalle, Cataldo Procacci, Davide Re, Luca Degli Esposti","doi":"10.23736/S2724-5683.24.06626-2","DOIUrl":"https://doi.org/10.23736/S2724-5683.24.06626-2","url":null,"abstract":"<p><strong>Background: </strong>PCSK9 inhibitors (PCSK9i) in combination with high-dose statins can reduce LDL-cholesterol (LDL-C) levels by 50-60% over statin monotherapy. This analysis investigated biochemical (LDL-C reduction) and economic outcomes in Italian patients treated with PCSK9i or potentially eligible but untreated.</p><p><strong>Methods: </strong>Administrative databases of healthcare institutions covering around 5 million residents were used to identify patients with PCSK9i prescriptions or potentially eligible-untreated patients between 2017 and Oct-2022. Outcomes were assessed during follow-up in cohorts balanced for baseline covariates by propensity score matching (PSM).</p><p><strong>Results: </strong>After PSM-balancing, 2649 treated and 2649 potentially eligible-untreated patients were included: mean age 64.4-64.7 years, 70-68% males, 92-93% with hypertension, 24-25% with diabetes, and 87% with previous atherosclerotic/cardiovascular events. During follow-up, PCSK9i-treated patients versus untreated/eligible showed a reduction of LDL-C levels (68.9±43.9 vs. 100.4±34.6 mg/dL, P<0.0001), hospitalization rates for heart attack (4.5% vs. 6.8%, P=0.0069), heart failure (4.5% vs. 6.6%, P=0.010), and lower all-cause mortality (3.2% vs. 9.5%, P<0.0001). The multivariate Cox model confirmed that eligible-untreated patients had a more than doubled mortality risk compared to the PCSK9i-treated ones (HR: 2.291, 95%CI: 1.651-3.178, P<0.0001). Although mean annualized total healthcare costs were higher in PCSK9i-treated versus untreated/eligible patients (€6745 vs. €4343, P<0.0001), because of the higher drug costs, PCSK9i therapy was associated with reduced expenses for hospitalizations (€1113 vs. €1687, P<0.0001) and specialist outpatient services (€386 vs. €787, P<0.0001).</p><p><strong>Conclusions: </strong>The real-world analysis suggests that therapy with PCSK9i resulted in reduced LDL-C levels, lower mortality rates and cost savings for hospitalizations and specialist services.</p>","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144001711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A tribute to the 60 years of angioplasty celebrating January 16th, 1964's first angioplasty by Charles Dotter: voices from the past, messages to build the future.","authors":"Jean Marco, Chiara DE Biase, Luigi Spadafora, Emanuele Barbato, Davide Capodanno, Francesco Saia, Salvatore DE Rosa, Elad Asher, Mattia Galli, Marco Bernardi, Pierre Sabouret","doi":"10.23736/S2724-5683.25.06571-8","DOIUrl":"https://doi.org/10.23736/S2724-5683.25.06571-8","url":null,"abstract":"<p><p>Charles T. Dotter is a recognized pioneer of interventional cardiology as much as the inventor of the angioplasty balloon himself, Andreas R. Grüntzig. Yet, despite Dotter's pioneering role in developing transluminal angioplasty, a recent survey revealed a significant lack of awareness among younger interventional cardiologists and fellows about his contributions, contrasting sharply with their familiarity with Grüntzig. We thereby shed light on Dotter's innovations and the reasons behind his relative obscurity in contemporary discourse, urging the medical community to embrace the lessons from his journey for future success. We explicitly focus on Dotter's early achievements, including his groundbreaking work in 1964, where he performed the first transluminal angioplasty, laying the groundwork for what would become a cornerstone in vascular intervention and creating the eponymous Dotter effect. Despite the initial resistance and skepticism, Dotter's methods eventually found their way to Europe, influencing Grüntzig and leading to the development of the balloon catheter. We also meticulously trace the evolution of angioplasty from Dotter's early experiments to Grüntzig's refinement of the technique and its application in coronary arteries, underscoring the pivotal moments and challenges encountered along the way. Dotter's obscurity stems from a combination of factors, including his confrontational approach and the reluctance of the medical establishment to embrace his radical ideas. Indeed, Dotter's story offers invaluable lessons on the importance of teamwork, perseverance, and the need for a supportive community to foster innovation in medicine.</p>","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144023297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for recurrence of persistent atrial fibrillation after radiofrequency ablation and correlation with plasma miRNA expression.","authors":"Beibei Ren, Shanglang Cai, Maojing Wang","doi":"10.23736/S2724-5683.24.06402-0","DOIUrl":"https://doi.org/10.23736/S2724-5683.24.06402-0","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;This study was to investigate the risk factors for recurrence after radiofrequency ablation (RFCA) in patients with persistent atrial fibrillation (PeAF) and analyse its correlation with plasma microribonucleic acid (miRNA) expression based on ultrasound cardiograms.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A total of 126 PeAF patients who underwent RFCA were selected as the research subjects (AF group), and 126 healthy subjects matched by gender and age were included as the control (control group). The basic data and biochemical indexes of the included research subjects were collected, and the subjects were followed up for one year after surgery. According to AF recurrence, all research subjects were divided into the recurrence group (45 cases) and the unpredictable group (81 cases). The t-test or Mann-Whitney U Test was adopted to compare B-type natriuretic peptide (BNP), uric acid (UA), glycosylated hemoglobin (HbA&lt;inf&gt;1c&lt;/inf&gt;), and other biochemical indicators among patients in recurrence group and unpredictable group. In addition, left atrial diameter (LAD), left atrial volume (LAV), and left atrial ejection fraction (LAEF) were measured in both groups of patients. Logistic regression analysis was performed to identify the primary risk factors for recurrence among patients with PeAF after RFCA. Furthermore, the receiver operating characteristic (ROC) curve was used to compare the area under the curve (AUC) of the identified risk factors.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;AF duration in the recurrence group was shorter than that in the unpredictable group (P&lt;0.01). The proportion of patients with a CHADS2 score of two or above in the recurrence group was significantly higher than that in the unpredictable group (P&lt;0.05) in addition to UA (P&lt;0.05) and BNP (P&lt;0.001). Similarly, the LAD and LAV in the recurrence group were significantly higher (P&lt;0.01), and LAEF was also found to be superior (P&lt;0.05) in comparison to the unpredictable group. The relative expressions of plasma miRNA-150 and miRNA-133 of the patients in the AF group were remarkably reduced compared with those in the control group (P&lt;0.05), while the relative expressions of miRNA-206, miRNA-21, miRNA-31, miRNA-27b, and miRNA-328 were all significantly increased (P&lt;0.05) in contrast to those in the control group, and the plasma miRNA-21 (P&lt;0.001) and miRNA-27b (P&lt;0.05) expression of the patients in the recurrence group were significantly higher than that in the unpredictable group. AF duration (odds ratio (OR) = 1.182, 95% confidence interval (CI): 1.021~1.357), LAD (OR=2.066, 95% CI: 1.203~4.491), miRNA-21 (OR=1.253, 95% CI: 1.012-1.647), and miRNA-27b (OR=1.186, 95% CI: 1.006-1.391) were all correlated with recurrence among patients with PeAF after RFCA (P&lt;0.05). The AUCs of AF duration, LAD, miRNA-21, and miRNA-27b LAD were found to be 0.654, 0.703, 0.795, and 0.815, respectively. The sensitivity values were 0.687, 0.701, 0.734, and 0.789, while the correspo","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144018253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}